Видео с ютуба Fda Cber Director

FDA Direct: Catching Up on Agency Reforms

Efficient Communication Reduces Regulatory Uncertainty — CBER Director, US FDA

FDA Direct with Dr. Martin Makary, FDA Commissioner

FDA CBER Director Dr. Peter Marks Discusses Industry Growth, Collaboration and Communication

The More Data We Have, the Better - CBER Director, US FDA

Preview: CBER Director Peter Marks Discusses FDA's Credibility at ARM's 2020 Meeting on the Mesa

What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago

OTP Town Hall: Gene Therapy Manufacturing CMC & Facility Readiness for BLAs & Post-licensure Changes

Watch CNBC's full interview with FDA Commissioner Dr. Marty Makary

Dr. Vinay Prasad Keynote Address - NORD Scientific Symposium

Director of FDA's CBER, Peter Marks, M.D., Ph.D. on COVID-19 Vaccine Confidence

Keeping Pace with CGT, Dr Peter Marks, Director CBER, FDA

Dissecting the Direction of CDER and CBER with Paul Kim

FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

FDA-NIH 2024 | D1S10 - CBER’s CMC Considerations for Early Phase Studies of Cell and Gene Therapy...

FDA | NIH : Regulatory Do’s and Don’ts: Tips from FDA: CBER Presentations

FDA Basics - CBER - Mini-Sentinel/Sentinel Activities Including Prism and Bloodscan

FDA Roundtable on Cell and Gene Therapy

FDA Appoints Dr. Vinay Prasad as New Head of Vaccines and Biologics Division

FDA CBER Cell Therapies Workshop: Closing - Insights and Remarks from Keynote Speaker